“We have the first device to treat macular telangiectasia type 2, which has been through the clinical trial program, and the long-term results up to 9 years find that it is still relatively well ...
2-Year U.S. Treasury Note Continuous Contract $102.914 0.027 0.03% 5-Year U.S. Treasury Note Continuous Contract $106.602 0.102 0.10% 10-Year U.S. Treasury Note Continuous Contract $109.203 0.172 ...
DAX Futures 21589.00 40.00 0.19% ...
Background Leber's hereditary optic neuropathy (LHON) and a multiple sclerosis (MS)-like illness appear to coexist 50 times more frequently than would be expected by chance. This association of LHON ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback